GINA VALENTE-MOORE: Open Payments
NPI 1336337484 · JAMESTOWN, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$11,016 in 76 payments from 14 companies in 2025. Trend: 2023 $6,039 · 2024 $7,285 · 2025 $11,016
Speaker / faculty: $5,110Travel & lodging: $3,641Food & beverage: $2,265
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 27 | $9,615 |
| ABBVIE INC. | 22 | $696 |
| Corcept Therapeutics | 5 | $186 |
| Janssen Biotech, Inc. | 5 | $120 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $105 |
| Novo Nordisk Inc | 2 | $53 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $49 |
| GENZYME CORPORATION | 1 | $36 |
| Lilly USA, LLC | 1 | $25 |
Products named: Epclusa, RINVOQ, MAVYRET, SKYRIZI, Korlym, TREMFYA, XIFAXAN, HETLIOZ.
Industry payments across CA — which companies pay providers there.
